1887

Microbiology Society logo

Volume 163, Issue 10

Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery Free

Abstract

is the aetiological agent of tuberculosis (TB) and is the leading bacterial cause of mortality and morbidity in the world. One third of the world’s population is infected with TB, and in conjunction with HIV represents a serious problem that urgently needs addressing. TB is a disease of poverty and mostly affects young adults in their productive years, primarily in the developing world. The most recent report from the World Health Organisation states that 8 million new cases of TB were reported and that ~1.5 million people died from TB. The efficacy of treatment is threatened by the emergence of multi-drug and extensively drug-resistant strains of . It can be argued that, globally, is the single most important infectious agent affecting mankind. Our research aims to establish an academic-industrial partnership with the goal of discovering new drug targets and hit-to-lead new chemical entities for TB drug discovery.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Colworth , drug discovery , Mycobacterium tuberuclosis , screening and Tuberculosis
© 2017 The Authors
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.000522
2017-10-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/micro/163/10/1385.html?itemId=/content/journal/micro/10.1099/mic.0.000522&mimeType=html&fmt=ahah

References

  1. United Nations Draft Outcome Document of the United Nations Summit for the Adoption of the Post-2015 Development Agenda New York: Sixty-ninth session of the General Assembly of the United Nations; 2015
     [Google Scholar]
  2. World Health Organisation TB Fast Sheet No. 104 Geneva: World Health Organization; 2014
     [Google Scholar]
  3. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223–227 [View Article][PubMed]
     [Google Scholar]
  4. Bloemberg GV, Keller PM, Stucki D, Stuckia D, Trauner A et al. Acquired resistance to bedaquiline and delamanid in therapy for Tuberculosis. N Engl J Med 2015; 373:1986–1988 [View Article][PubMed]
     [Google Scholar]
  5. Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol 2013; 8:1071–1080 [View Article][PubMed]
     [Google Scholar]
  6. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6:29–40 [View Article][PubMed]
     [Google Scholar]
  7. Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E et al. Fueling open-source drug discovery: 177 small-molecule leads against Tuberculosis. ChemMedChem 2013; 8:313–321 [View Article][PubMed]
     [Google Scholar]
  8. Cooper CB. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. J Med Chem 2013; 56:7755–7760 [View Article][PubMed]
     [Google Scholar]
  9. Grant SS, Kawate T, Nag PP, Silvis MR, Gordon K et al. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem Biol 2013; 8:2224–2234 [View Article][PubMed]
     [Google Scholar]
  10. Reynolds RC, Ananthan S, Faaleolea E, Hobrath JV, Kwong CD et al. High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. Tuberculosis 2012; 92:72–83 [View Article][PubMed]
     [Google Scholar]
  11. Manjunatha UH, Smith PW. Perspective: challenges and opportunities in TB drug discovery from phenotypic screening. Bioorg Med Chem 2015; 23:5087–5097 [View Article][PubMed]
     [Google Scholar]
  12. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358:591–593 [View Article][PubMed]
     [Google Scholar]
  13. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227–230 [View Article][PubMed]
     [Google Scholar]
  14. Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009; 324:801–804 [View Article][PubMed]
     [Google Scholar]
  15. Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci USA 2012; 109:11354–11359 [View Article][PubMed]
     [Google Scholar]
  16. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 2012; 4:150ra121 [View Article][PubMed]
     [Google Scholar]
  17. Grover S, Alderwick LJ, Mishra AK, Krumbach K, Marienhagen J et al. Benzothiazinones mediate killing of corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis. J Biol Chem 2014; 289:6177–6187 [View Article][PubMed]
     [Google Scholar]
  18. Remuiñán MJ, Pérez-Herrán E, Rullás J, Alemparte C, Martínez-Hoyos M et al. Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One 2013; 8:e60933 [View Article][PubMed]
     [Google Scholar]
  19. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 2012; 8:334–341 [View Article][PubMed]
     [Google Scholar]
  20. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 2012; 56:324–331 [View Article][PubMed]
     [Google Scholar]
  21. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V et al. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 2014; 57:3126–3139 [View Article][PubMed]
     [Google Scholar]
  22. Li W, Upadhyay A, Fontes FL, North EJ, Wang Y et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58:6413–6423 [View Article][PubMed]
     [Google Scholar]
  23. Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR et al. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med 2013; 5:214ra168 [View Article][PubMed]
     [Google Scholar]
  24. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56:1797–1809 [View Article][PubMed]
     [Google Scholar]
  25. Cox JA, Abrahams KA, Alemparte C, Ghidelli-Disse S, Rullas J et al. THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. Nat Microbiol 2016; 1:15006 [View Article][PubMed]
     [Google Scholar]
  26. Jankute M, Cox JA, Harrison J, Besra GS. Assembly of the Mycobacterial Cell Wall. Annu Rev Microbiol 2015; 69:405–423 [View Article][PubMed]
     [Google Scholar]
  27. Abrahams KA, Chung CW, Ghidelli-Disse S, Rullas J, Rebollo-López MJ et al. Identification of KasA as the cellular target of an anti-tubercular scaffold. Nat Commun 2016; 7:12581 [View Article][PubMed]
     [Google Scholar]
  28. Bhatt A, Kremer L, Dai AZ, Sacchettini JC, Jacobs WR. Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis. J Bacteriol 2005; 187:7596–7606 [View Article][PubMed]
     [Google Scholar]
  29. Kremer L, Douglas JD, Baulard AR, Morehouse C, Guy MR et al. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 2000; 275:16857–16864 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.000522
Loading
Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery
Microbiology 163, 1385 (2017); https://doi.org/10.1099/mic.0.000522
/content/journal/micro/10.1099/mic.0.000522
/content/journal/micro/10.1099/mic.0.000522
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error